Business
Directors' / PDMR dealing
Futura Medical plc announced that its Directors and persons closely associated subscribed for an aggregate of 6,000,000 Ordinary Shares at 1 pence per share, totaling £60,000, as part of a fundraise. Specifically, Alex Duggan subscribed for 5,000,000 shares, Angela Hildreth for 500,000 shares, and Ken James for 500,000 shares. These transactions, which occurred on December 4, 2025, represent a direct investment by key management personnel into the company, potentially signaling confidence in its future prospects. Disclaimer*
About this update from Futura Medical Plc
[{"type":"text","content":"\n\n8 December 2025\nFutura Medical plc\n(\"Futura\" or the \"Company\")\nDirectors' / PDMR Dealing\nFutura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, confirms that the following Directors and persons closely associated subscribed for an aggregate of 6,000,000 Ordinary Shares in the Company pursuant to the Fundraise announced on 13 November 2025.\n \nDetails are as below:\n \n\n\n\n\nDirector\n\n\nNumber of New Shares\n\n\nIssue Price per Ordinary Share\n\n\nTotal number of Ordinary Shares held following Admission\n\n\n \n\n\nPercentage of Enlarged Share Capital\n\n\n\n\nAlex Duggan*\n\n\n5,000,000\n\n\n1 pence\n\n\n5,000,000\n\n\n\n\n\n0.86%\n\n\n\n\nAngela Hildreth\n\n\n500,000\n\n\n1 pence\n\n\n642,857\n\n\n\n\n\n0.11%\n\n\n\n\nKen James\n\n\n500,000\n\n\n1 pence\n\n\n799,501\n\n\n\n\n\n0.14%\n\n\n\n\n \n \nFurther disclosures are contained in the tables below. \n \n· Alex Duggan's shares were purchased by a wholly owned entity, Appia Healthcare Limited.\n \n \nCapitalised terms not defined in this announced have the meanings given to them in the Fundraise Announcement dated 13 November 2025.\n \nENDS\n \nContacts:\n\n\n\n\nFutura Medical plc\n \n \n \n\n\nAlex Duggan\nChief Executive Officer\nAngela Hildreth\nFinance Director and COO\n \n\n\[email protected]\n+44 (0)1483 685 670\nwww.futuramedical.com\n \n\n\n\n\nPanmure Liberum\nNominated Adviser\nand Broker\n \n\n\nEmma Earl, Will Goode, Mark Rogers (Corporate Finance)\nRupert Dearden (Corporate Broking)\n\n\n+44 (0)20 3100 2000\n \n \n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nTurner Pope Investments (TPI) Ltd\nBroker\n \n\n\nGuy McDougall / Andrew Thacker\n\n\n+44 (0) 20 3657 0050\n \n\n\n\n\nAlma Strategic Communications\n\n\nRebecca Sanders-Hewett\nSam Modlin\nEmma Thompson\n\n\n+44 (0)20 3405 0205\[email protected]\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n \nNotes to Editors:\nFutura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon® and development products W...